CYCN
Cyclerion Therapeutics, Inc.
Price Chart
Latest Quote
$3.20
+0.02 (+0.63%)
Current Price
| Previous Close | $3.18 |
| Open | $3.22 |
| Day High | $3.30 |
| Day Low | $3.20 |
| Volume | 36,109 |
Stock Information
| Shares Outstanding | 4.33M |
| Cash Equivalents | $2.82M |
| Revenue | $1.99M |
| Net Income | $-5.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $13.86M |
| EPS (TTM) | $-1.31 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.75M |
| Sales | $1.99M |
| Income | $-5.28M |
| Book/sh | $1.60 |
| Cash/sh | $0.65 |
| Employees | 1 |
Financial Ratios
| Quick Ratio | 1.65 |
| Current Ratio | 1.80 |
Returns & Margins
| ROA | -45.81% |
| ROE | -67.77% |
| Gross Margin | 17.06% |
| Operating Margin | -337.43% |
| Profit Margin | -264.73% |
Ownership
| Insider Ownership | 24.56% |
| Institutional Ownership | 4.32% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.44 |
| P/S | 6.95 |
| P/B | 2.00 |
Analyst Data
| Recommendation | none |
| Target Price | $8.00 |
Technical Indicators
| SMA20 | $3.12 |
| SMA50 | $3.10 |
| SMA200 | $2.15 |
| RSI | 53.73 |
| ATR | 0.1529 |
| Shares Float | 3.49M |
| Short Float | 0.68% |
| Short Ratio | 0.35 |
| Volatility | 1.77 |
| Rel Volume | 1.42 |
Performance History
| Week | -0.31% |
| Month | +6.67% |
| Quarter | +111.92% |
| 6 Months | +109.15% |
| YTD | +138.81% |
| Year | +2.99% |
| 3 Years | -29.52% |
| 5 Years | -95.97% |
| 10 Years | -98.72% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.20 | 43,900 |
| 2026-06-17 | $3.18 | 20,500 |
| 2026-06-16 | $3.18 | 62,500 |
| 2026-06-15 | $3.18 | 37,000 |
| 2026-06-12 | $3.25 | 39,100 |
| 2026-06-11 | $3.21 | 21,800 |
| 2026-06-10 | $3.09 | 21,000 |
| 2026-06-09 | $3.00 | 23,900 |
| 2026-06-08 | $3.01 | 27,900 |
| 2026-06-05 | $2.98 | 24,400 |
| 2026-06-04 | $3.06 | 42,400 |
| 2026-06-03 | $3.00 | 31,600 |
| 2026-06-02 | $3.02 | 31,100 |
| 2026-06-01 | $3.08 | 27,100 |
| 2026-05-29 | $3.15 | 35,100 |
| 2026-05-28 | $3.18 | 22,800 |
| 2026-05-27 | $3.15 | 23,400 |
| 2026-05-26 | $3.20 | 29,200 |
| 2026-05-22 | $3.18 | 36,400 |
| 2026-05-21 | $3.16 | 15,500 |
| 2026-05-20 | $3.08 | 59,600 |
| 2026-05-19 | $3.00 | 38,700 |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
đ° Latest News
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimerâs Pipeline
Insider Monkey âĸ 2026-04-20T14:15:01Z
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?
Barchart âĸ 2026-04-02T13:15:38Z
Top Midday Gainers
MT Newswires âĸ 2026-04-01T17:51:30ZBC-Most Active Stocks
Associated Press Finance âĸ 2026-01-06T15:30:18ZAkebia Therapeutics Sets Rare Kidney Drug Plan After Q32 Bio Deal
MT Newswires âĸ 2025-12-01T13:40:54ZInsider Stock Buying Reaches US$525.0k On Cyclerion Therapeutics
Simply Wall St. âĸ 2025-11-11T14:17:12Z
EXCLUSIVE: Cycurion Wins $1 Million+ Contract To Modernize Federal Emergency Warning Network
Benzinga âĸ 2025-11-10T14:16:11Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $2,074,000 | $2,000,000 | $0 | $297,000 |
| Operating Revenue | $2,074,000 | $2,000,000 | $0 | $297,000 |
| Expenses | ||||
| Total Expenses | $7,047,000 | $5,628,000 | $9,647,000 | $18,837,000 |
| Other Income Expense | $1,317,000 | $363,000 | $-3,304,000 | - |
| Net Non Operating Interest Income Expense | $128,000 | $208,000 | $358,000 | $294,000 |
| Operating Expense | $7,047,000 | $5,628,000 | $9,647,000 | $18,837,000 |
| General And Administrative Expense | $6,088,000 | $5,342,000 | $8,132,000 | $12,858,000 |
| Other Non Operating Income Expenses | - | $363,000 | - | - |
| Total Other Finance Cost | - | - | - | $-294,000 |
| Other Operating Expenses | - | - | - | $-1,328,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,528,000 | $-3,057,000 | $-12,593,000 | $-18,246,000 |
| Net Interest Income | $128,000 | $208,000 | $358,000 | $294,000 |
| Interest Income | $128,000 | $208,000 | $358,000 | $294,000 |
| Normalized Income | $-4,845,000 | $-3,420,000 | $-9,289,000 | $-18,246,000 |
| Net Income From Continuing And Discontinued Operation | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Total Operating Income As Reported | $-4,973,000 | $-3,628,000 | $-12,951,000 | $-18,540,000 |
| Net Income Common Stockholders | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Net Income | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Net Income Including Noncontrolling Interests | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Net Income Continuous Operations | $-3,528,000 | $-3,057,000 | $-12,593,000 | $-18,246,000 |
| Pretax Income | $-3,528,000 | $-3,057,000 | $-12,593,000 | $-18,246,000 |
| Special Income Charges | $1,317,000 | $363,000 | $-3,304,000 | $0 |
| Interest Income Non Operating | $128,000 | $208,000 | $358,000 | $294,000 |
| Operating Income | $-4,973,000 | $-3,628,000 | $-9,647,000 | $-18,540,000 |
| Net Income Discontinuous Operations | - | $0 | $7,330,000 | $-25,832,000 |
| Per Share | ||||
| Diluted EPS | $-1.11 | $-1.21 | $-2.25 | $-20.28 |
| Basic EPS | $-1.11 | $-1.21 | $-2.25 | $-20.28 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,290,000 | $-3,991,000 | $-6,343,000 | $-18,475,000 |
| Total Unusual Items | $1,317,000 | $363,000 | $-3,304,000 | $0 |
| Total Unusual Items Excluding Goodwill | $1,317,000 | $363,000 | $-3,304,000 | $0 |
| EBITDA (Bullshit earnings) | $-4,973,000 | $-3,628,000 | $-9,647,000 | $-18,475,000 |
| EBIT | $-4,973,000 | $-3,628,000 | $-9,647,000 | $-18,540,000 |
| Diluted Average Shares | $3,181,000 | $2,518,000 | $2,338,000 | $2,173,000 |
| Basic Average Shares | $3,181,000 | $2,518,000 | $2,338,000 | $2,173,000 |
| Diluted NI Availto Com Stockholders | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Other Special Charges | $-1,317,000 | $-363,000 | - | - |
| Research And Development | $959,000 | $286,000 | $1,515,000 | $5,979,000 |
| Selling General And Administration | $6,088,000 | $5,342,000 | $8,132,000 | $12,858,000 |
| Other Gand A | $6,088,000 | $5,342,000 | $8,132,000 | $12,858,000 |
| Impairment Of Capital Assets | - | $0 | $3,304,000 | $0 |
| Reconciled Depreciation | - | - | $0 | $65,000 |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Total Assets | $9,985,000 | $9,575,000 | $13,374,000 | $18,079,000 |
| Total Non Current Assets | $5,350,000 | $5,350,000 | $5,350,000 | $3,259,000 |
| Current Assets | $4,635,000 | $4,225,000 | $8,024,000 | $14,820,000 |
| Other Current Assets | $11,000 | $16,000 | $11,000 | $537,000 |
| Prepaid Assets | $384,000 | $421,000 | $442,000 | $805,000 |
| Receivables | $1,000,000 | $556,000 | $0 | $96,000 |
| Accounts Receivable | $1,000,000 | $556,000 | $0 | $96,000 |
| Cash Cash Equivalents And Short Term Investments | $3,240,000 | $3,232,000 | $7,571,000 | $13,382,000 |
| Cash And Cash Equivalents | $3,240,000 | $3,232,000 | $7,571,000 | $13,382,000 |
| Other Non Current Assets | - | - | - | $2,041,000 |
| Debt | ||||
| Total Debt | - | - | - | - |
| Long Term Debt And Capital Lease Obligation | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $900,000 | $725,000 | $2,086,000 | $7,627,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $900,000 | $725,000 | $2,086,000 | $7,627,000 |
| Other Current Liabilities | $38,000 | $30,000 | $113,000 | $68,000 |
| Payables And Accrued Expenses | $849,000 | $662,000 | $1,973,000 | $6,326,000 |
| Payables | $508,000 | $390,000 | $1,198,000 | $2,970,000 |
| Accounts Payable | $508,000 | $390,000 | $1,198,000 | $2,970,000 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Total Equity Gross Minority Interest | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Stockholders Equity | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Retained Earnings | $-271,020,000 | $-267,492,000 | $-264,417,000 | $-259,154,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $-12,000 | $-20,000 |
| Other Equity Adjustments | - | - | $-12,000 | $-20,000 |
| Other | ||||
| Ordinary Shares Number | $3,821,236 | $2,545,922 | $2,474,159 | $2,175,936 |
| Share Issued | $3,821,236 | $2,545,922 | $2,474,159 | $2,175,936 |
| Tangible Book Value | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Invested Capital | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Working Capital | $3,735,000 | $3,500,000 | $5,938,000 | $7,193,000 |
| Total Capitalization | $9,085,000 | $8,850,000 | $11,288,000 | $10,452,000 |
| Additional Paid In Capital | $280,105,000 | $276,342,000 | $275,717,000 | $269,626,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $13,000 | $33,000 | $0 | $1,233,000 |
| Current Accrued Expenses | $341,000 | $272,000 | $775,000 | $3,356,000 |
| Investments And Advances | $5,350,000 | $5,350,000 | $5,350,000 | $0 |
| Other Investments | $5,350,000 | $5,350,000 | $5,350,000 | $0 |
| Net PPE | - | $0 | $0 | $1,218,000 |
| Accumulated Depreciation | - | $-126,000 | $-126,000 | $-2,181,000 |
| Gross PPE | - | $126,000 | $126,000 | $3,399,000 |
| Machinery Furniture Equipment | - | $126,000 | $126,000 | $2,181,000 |
| Treasury Shares Number | - | - | $170,937 | - |
| Other Properties | - | - | - | $1,218,000 |
| Capital Lease Obligations | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
| Current Capital Lease Obligation | - | - | - | - |
| Leases | - | - | - | - |
| Properties | - | - | - | - |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,314,000 | $-4,333,000 | $-21,245,000 | $-40,611,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,314,000 | $-4,333,000 | $-21,245,000 | $-40,611,000 |
| Cash Flow From Continuing Operating Activities | $-3,314,000 | $-4,333,000 | $-21,245,000 | $-40,611,000 |
| Cash From Discontinued Operating Activities | - | - | $-15,752,000 | $0 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $10,402,000 | $0 |
| Cash From Discontinued Investing Activities | - | $0 | $10,402,000 | $0 |
| Cash Flow From Continuing Investing Activities | - | - | - | $0 |
| Capital Expenditure | - | - | - | - |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-130,000 | $0 | - | - |
| Issuance Of Capital Stock | $1,375,000 | $0 | - | $0 |
| Financing Cash Flow | $3,322,000 | $0 | $5,024,000 | $29,000 |
| Cash Flow From Continuing Financing Activities | $3,322,000 | $0 | $5,024,000 | $29,000 |
| Net Other Financing Charges | $2,077,000 | - | - | - |
| Net Common Stock Issuance | $1,245,000 | $0 | - | $0 |
| Common Stock Issuance | $1,375,000 | $0 | - | $0 |
| Other | ||||
| End Cash Position | $3,240,000 | $3,232,000 | $7,571,000 | $13,382,000 |
| Beginning Cash Position | $3,232,000 | $7,571,000 | $13,382,000 | $53,961,000 |
| Effect Of Exchange Rate Changes | $0 | $-6,000 | $8,000 | $3,000 |
| Changes In Cash | $8,000 | $-4,333,000 | $-5,819,000 | $-40,582,000 |
| Common Stock Payments | $-130,000 | $0 | - | - |
| Change In Working Capital | $-227,000 | $-1,538,000 | $-4,601,000 | $-2,850,000 |
| Change In Other Current Assets | $5,000 | $-5,000 | $481,000 | $481,000 |
| Change In Payables And Accrued Expense | $175,000 | $-998,000 | $-5,541,000 | $-3,458,000 |
| Change In Accrued Expense | $57,000 | $-553,000 | $-3,769,000 | $-4,600,000 |
| Change In Payable | $118,000 | $-445,000 | $-1,772,000 | $1,142,000 |
| Change In Account Payable | $118,000 | $-445,000 | $-1,772,000 | $1,142,000 |
| Change In Prepaid Assets | $37,000 | $21,000 | $363,000 | $123,000 |
| Change In Receivables | $-444,000 | $-556,000 | $96,000 | $4,000 |
| Changes In Account Receivables | $-444,000 | $-556,000 | $96,000 | $4,000 |
| Stock Based Compensation | $441,000 | $625,000 | $1,067,000 | $6,252,000 |
| Net Income From Continuing Operations | $-3,528,000 | $-3,057,000 | $-5,263,000 | $-44,078,000 |
| Proceeds From Stock Option Exercised | - | $0 | $5,024,000 | $29,000 |
| Other Non Cash Items | - | $-363,000 | $-15,752,000 | - |
| Asset Impairment Charge | - | $0 | $3,304,000 | $0 |
| Depreciation Amortization Depletion | - | - | $0 | $65,000 |
| Depreciation And Amortization | - | - | $0 | $65,000 |
| Net PPE Purchase And Sale | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Purchase Of PPE | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Net Issuance Payments Of Debt | - | - | - | - |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-20